The global coagulation analyzer market size reached US$ 5.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.5 Billion by 2028, exhibiting a growth rate (CAGR) of 7.7% during 2023-2028.
Coagulation, also known as hematology, is a process that enables the blood to create a clot to heal a wound. Physicians primarily use coagulation analyzers for quantifying and classifying blood cells. Different types of coagulation tests, such as PT, APTT, ACT, etc., are carried out for assessing blood clotting function in patients. Most of the hematology analyzers are capable of providing information about hemoglobin in red blood cells (RBCs), corpuscular data, platelet counts and hematocrit levels. However, some new machines have been developed to measure two specialized cell types, which include nucleated RBCs and immature white cells. At present, coagulation analyzers are experiencing a rise in their demand on account of consistent growth in the population suffering from blood disorders and lifestyle diseases.
Over the past decade, rapid advancements in technology and the introduction of new coagulation analyzer tests have led to an increase in the quality and efficiency of hemostasis laboratories. Some of the modern complex coagulators also possess high throughput, flexibility and reliability. Other than this, they provide improved accuracy and precision, and easy-to-use advanced software provided with in-built graphs and calibration curves. Moreover, there has been a significant rise in the prevalence of cardiac diseases and blood disorders, which has created the need for improved coagulation analyzers across the globe. Besides this, the sales of coagulation analyzers are positively being influenced by the increasing number of hospitals, diagnostic centers and research institutes established worldwide.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global coagulation analyzer market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on testing type, product type, technology type and end user.
Breakup by Testing Type:
Prothrombin Time Testing (PT)
Activated Partial Thromboplastin Time Testing (APTT)
Activated Clotting Time Testing (ACT)
Platelet Function Testing
Anti-Factor Xa Testing
Breakup by Product Type:
Breakup by Technology Type:
Breakup by End User:
Breakup by Region:
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Roche Diagnostics (F. Hoffmann-La Roche Ltd.), Nihon Kohden, Sysmex Corporation, Siemens Healthineers Company, Thermo Fisher Scientific Inc., Helena Laboratories Corporation, DIAGNOSTICA STAGO, Instrumentation Laboratory Company, etc.
Base Year of the Analysis
Testing Type, Product Type, Technology Type, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Abbott Laboratories, Roche Diagnostics (F. Hoffmann-La Roche Ltd.), Nihon Kohden, Sysmex Corporation, Siemens Healthineers Company, Thermo Fisher Scientific Inc., Helena Laboratories Corporation, DIAGNOSTICA STAGO and Instrumentation Laboratory Company
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global coagulation analyzer market was valued at US$ 5.4 Billion in 2022.
We expect the global coagulation analyzer market to exhibit a CAGR of 7.7% during 2023-2028.
The rising prevalence of cardiac diseases and blood disorders, along with the increasing adoption of coagulation analyzer, as they offer improved accuracy and precision and easy-to-use advanced software provided with in-built graphs and calibration curves, is primarily driving the global coagulation analyzer market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective clotting deficiencies tests to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for coagulation analyzer.
Based on the testing type, the global coagulation analyzer market can be segmented into Prothrombin Time Testing (PT), fibrinogen testing, Activated Partial Thromboplastin Time Testing (APTT), Activated Clotting Time Testing (ACT), D-dimer testing, platelet function testing, anti-factor Xa testing, and others. Currently, Prothrombin Time Testing (PT) holds the majority of the total market share.
Based on the product type, the global coagulation analyzer market has been divided into instruments/analyzers, reagents, consumables, and others. Among these, instruments/analyzers currently exhibit a clear dominance in the market.
Based on the technology type, the global coagulation analyzer market can be categorized into optical technology, mechanical technology, electrochemical technology, and others. Currently, optical technology accounts for the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global coagulation analyzer market include Abbott Laboratories, Roche Diagnostics (F. Hoffmann-La Roche Ltd.), Nihon Kohden, Sysmex Corporation, Siemens Healthineers Company, Thermo Fisher Scientific Inc., Helena Laboratories Corporation, DIAGNOSTICA STAGO, Instrumentation Laboratory Company, etc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.